Last reviewed · How we verify
LPCN 1144 Formulation B
LPCN 1144 Formulation B is a testosterone replacement therapy.
LPCN 1144 Formulation B is a testosterone replacement therapy. Used for Treatment of hypogonadism in men.
At a glance
| Generic name | LPCN 1144 Formulation B |
|---|---|
| Also known as | testosterone undecanoate with d-alpha tocopherol |
| Sponsor | Lipocine Inc. |
| Drug class | testosterone replacement therapy |
| Target | androgen receptor |
| Modality | Small molecule |
| Therapeutic area | Urology |
| Phase | Phase 2 |
Mechanism of action
It works by increasing testosterone levels in the body, which can help alleviate symptoms of hypogonadism such as low libido and fatigue. LPCN 1144 Formulation B is designed to provide a more consistent and predictable release of testosterone compared to traditional formulations.
Approved indications
- Treatment of hypogonadism in men
Common side effects
- Erectile dysfunction
- Acne
- Hypertension
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LPCN 1144 Formulation B CI brief — competitive landscape report
- LPCN 1144 Formulation B updates RSS · CI watch RSS
- Lipocine Inc. portfolio CI